Capstone Therapeutics

Capstone Therapeutics (OTCQB: CAPS) is a clinical-stage biotechnology company developing a new class of peptide drugs to serve cardiovascular patients with elevated cholesterol and triglyceride levels. Capstone’s lead molecule, AEM-28, has been granted Orphan Drug Designation by the FDA for the treatment of Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications such as Acute Coronary Syndrome, Peripheral Artery Disease, and Type 2 Diabetes.